Assessment of the efficacy of telithromycin simulating human exposures against S. pneumoniae with ribosomal mutations in a murine pneumonia model
- 30 June 2005
- journal article
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 25 (6) , 530-534
- https://doi.org/10.1016/j.ijantimicag.2005.02.014
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Pharmacodynamic Profile of Telithromycin against Macrolide- and Fluoroquinolone-Resistant Streptococcus pneumoniae in a Neutropenic Mouse Thigh ModelAntimicrobial Agents and Chemotherapy, 2005
- Macrolide Resistance by Ribosomal Mutation in Clinical Isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 StudyAntimicrobial Agents and Chemotherapy, 2003
- Influence of Macrolide Susceptibility on Efficacies of Clarithromycin and Azithromycin against Streptococcus pneumoniae in a Murine Lung Infection ModelAntimicrobial Agents and Chemotherapy, 2003
- Pharmacokinetics and Absolute Oral Bioavailability of an 800-mg Oral Dose of Telithromycin in Healthy Young and Elderly VolunteersChemotherapy, 2002
- Resistance amongStreptococcus pneumoniae:Implications for Drug SelectionClinical Infectious Diseases, 2002
- Pharmacodynamic Assessment of Clarithromycin in a Murine Model of Pneumococcal PneumoniaAntimicrobial Agents and Chemotherapy, 2002
- Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycinClinical Microbiology & Infection, 2001
- In Vivo Efficacy of the New Ketolide Telithromycin (HMR 3647) in Murine Infection ModelsAntimicrobial Agents and Chemotherapy, 2001
- Pharmacodynamics of Telithromycin In Vitro against Respiratory Tract PathogensAntimicrobial Agents and Chemotherapy, 2001
- Pharmacokinetics of the New Ketolide Telithromycin (HMR 3647) Administered in Ascending Single and Multiple DosesAntimicrobial Agents and Chemotherapy, 2001